1. Home
  2. BYRN vs TOI Comparison

BYRN vs TOI Comparison

Compare BYRN & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Byrna Technologies Inc.

BYRN

Byrna Technologies Inc.

HOLD

Current Price

$6.05

Market Cap

200.6M

Sector

Miscellaneous

ML Signal

HOLD

Logo The Oncology Institute Inc.

TOI

The Oncology Institute Inc.

HOLD

Current Price

$3.36

Market Cap

304.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BYRN
TOI
Founded
2005
2007
Country
United States
United States
Employees
N/A
641
Industry
Industrial Machinery/Components
Medical/Nursing Services
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
200.6M
304.4M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
BYRN
TOI
Price
$6.05
$3.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$23.17
$6.67
AVG Volume (30 Days)
593.8K
1.9M
Earning Date
04-09-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
$16,566,295.00
N/A
Revenue This Year
$17.30
$30.15
Revenue Next Year
$16.48
$25.77
P/E Ratio
$218.00
N/A
Revenue Growth
1692.08
N/A
52 Week Low
$5.56
$1.80
52 Week High
$33.56
$4.88

Technical Indicators

Market Signals
Indicator
BYRN
TOI
Relative Strength Index (RSI) 26.65 59.94
Support Level N/A $3.31
Resistance Level $21.98 $3.74
Average True Range (ATR) 0.68 0.23
MACD -0.20 0.01
Stochastic Oscillator 11.71 77.50

Price Performance

Historical Comparison
BYRN
TOI

About BYRN Byrna Technologies Inc.

Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.

About TOI The Oncology Institute Inc.

The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.

Share on Social Networks: